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Abstract
Background: The interleukin-6 receptor inhibitor sarilumab demonstrated efficacy in combination with conventional
synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy in patients with moderately to severely
active rheumatoid arthritis (RA) with an inadequate response (IR) or intolerant (INT) to methotrexate (MTX) or tumour
necrosis factor (TNF)-α inhibitors. This analysis investigated the efficacy and safety of sarilumab in patient subgroups.
Methods: Data were included from phase III studies: two placebo-controlled studies of subcutaneous sarilumab 150/200mg
every 2 weeks (q2w) either + MTX in MTX-IR patients (52 weeks) or + csDMARDs in TNF-IR/INT patients (24 weeks),
and a monotherapy study of sarilumab 200mg q2w vs. adalimumab 40mg q2w in MTX-IR/INT patients (24 weeks).
Prespecified and post hoc subgroups included patient demographics, disease characteristics, and prior treatments.
Prespecified and post hoc endpoints included clinical, radiographic, and physical function measures, and p values are
considered nominal. Safety was assessed during double-blind treatment.
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Results: The superiority of sarilumab (either as monotherapy vs. adalimumab or in combination with csDMARDs vs.
placebo + csDMARDs) across clinical endpoints was generally consistent across subgroups defined by patient
demographics, disease characteristics, and prior treatments, demonstrating the benefit of sarilumab treatment for a
wide range of patient types. Interaction p values of < 0.05 were consistently observed across studies only for baseline
anti-cyclic citrullinated peptide antibody (ACPA) status for American College of Rheumatology 20% response, but not
American College of Rheumatology 50% or 70% response. Adverse events and worsening laboratory parameters
occurred more frequently in sarilumab-treated vs. placebo-treated patients and were more frequent in the small
number of patients ≥ 65 years (n = 289) vs. patients < 65 years (n = 1819). Serious infections occurred in six patients
aged ≥ 65 years receiving sarilumab, although the incidence of serious infections was generally higher in patients aged
≥ 65 years regardless of treatment.
Conclusions: Apart from ACPA status, there were no consistent signals indicating differential effects of sarilumab in
any of the subpopulations assessed. Sarilumab demonstrated consistent efficacy and safety across a wide range of
patients with RA.
Trial registration: ClinicalTrials.gov NCT01061736, registered on February 03, 2010; ClinicalTrials.gov NCT01709578,
registered on October 18, 2012; ClinicalTrials.gov NCT02332590, registered on January 07, 2015
Keywords: Rheumatoid arthritis, Sarilumab, Interleukin-6, Adalimumab, csDMARDs, Methotrexate, Subpopulations
Background
Rheumatoid arthritis (RA) affects nearly 20 million
people worldwide [1] and is associated with substantial
morbidity and disability [2]. The consequences of RA
disease progression on patient health may be influenced
by multiple genetic and environmental factors [3], and
specific subpopulations of patients with RA can be char-
acterized on the basis of differences in demographic var-
iables, clinical features, and biomarkers, some of which
have been shown to be associated with disease outcomes
and therapeutic responses [4–9].
Characterization of subpopulations of patients most
likely to respond favourably or unfavourably to conven-
tional synthetic disease-modifying antirheumatic drugs
(csDMARDs) and/or biologic DMARDs (bDMARDs)
could help guide appropriate use of the many therapies
now available and improve patient outcomes. Obesity
and current smoking are independent predictors of fail-
ure to achieve adequate disease control after the first or
second csDMARD [10]. Studies have suggested that the
presence of anti-cyclic citrullinated peptide antibodies
(ACPA) may be associated with superior responses to
rituximab, adalimumab, and abatacept [11, 12], but also
increased mortality [13], and may mark an indication
for more intense RA treatment with csDMARDs and glu-
cocorticoids [14]. Furthermore, the European League
Against Rheumatism (EULAR) RA management recom-
mendations list the presence of rheumatoid factor (RF)
and/or ACPA as poor prognostic factors and recommend
that, if present, patients are treated with a bDMARD after
failure to achieve the target with initial methotrexate
(MTX) treatment [15]. However previous approaches to
define useful baseline characteristics that predict treat-
ment response have been largely unsuccessful due to
inconsistent findings, low predictive value, and lack of
validation [16].
Sarilumab is a human monoclonal antibody that binds
membrane-bound and soluble interleukin-6 (IL-6)
receptor-α to inhibit IL-6 signalling. Sarilumab is ap-
proved as a monotherapy or in combination with
csDMARDs for the treatment of adults with moderately
to severely active RA with an inadequate response (IR) or
intolerant (INT) to one or more csDMARDs. In phase III
clinical trials, sarilumab has demonstrated efficacy in pa-
tients with IR or who are INT to csDMARDs, including
MTX, and to tumour necrosis factor (TNF)-α inhibitors,
and it has demonstrated superiority as monotherapy vs.
adalimumab monotherapy for improving the signs and
symptoms of RA and physical function in patients with IR
or who are INT to MTX [17–19].
Here, we explore the efficacy, safety, and consistency
of treatment effects of sarilumab vs. placebo or adalimu-
mab across a range of predefined and post hoc patient




MOBILITY (NCT01061736; subsequently defined as the
MTX-IR combination study), TARGET (NCT01709578;
subsequently defined as the TNF-IR/INT combination
study), and MONARCH (NCT02332590; subsequently
defined as the monotherapy study) were phase III multi-
centre, randomized, controlled studies (RCTs). Study
protocols were approved by appropriate ethics commit-
tees/institutional review boards, and the trials were con-
ducted in accordance with the International Conference
on Harmonisation Guidelines for Good Clinical Practice
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and the Declaration of Helsinki. All patients provided
written informed consent before the initiation of study
procedures.
The study designs and patient eligibility criteria have
been described in full elsewhere [17–19]. In brief, the
MTX-IR combination study investigated subcutaneous
(SC) sarilumab 150 or 200 mg every 2 weeks (q2w) or
placebo (1:1:1 randomization) in combination with
weekly MTX for 52 weeks in adults with moderately to
severely active RA with MTX-IR [19]. In the TNF-IR/
INT combination study, adults with TNF-IR or who
were INT, with moderately to severely active RA, were
randomized (1:1:1) to receive SC sarilumab 150 or 200mg
q2w or placebo q2w in combination with background
csDMARDs for 24 weeks [18]. In the monotherapy study,
bDMARD-naive adults with MTX-IR or who were INT,
with moderately to severely active RA, were randomized
(1:1) to receive SC sarilumab 200mg q2w or SC adalimu-
mab 40mg q2w for 24 weeks [17].
Patient subpopulations
The baseline characteristics prespecified in the individual
trial protocols for efficacy analyses stratified by patient
subpopulations were age, sex, race (classified by the in-
vestigator), region, weight, body mass index (BMI),
smoking history, duration of RA, baseline RF and ACPA
status, and levels of C-reactive protein (CRP). The fol-
lowing were also prespecified for individual studies:
number of prior csDMARDs (MTX-IR and TNF-IR/INT
combination studies), prior bDMARD use (MTX-IR
combination study), number of previous anti-TNFs,
MTX vs. non-MTX use, background csDMARD use
(TNF-IR/INT combination study), baseline erythrocyte
sedimentation rate (ESR), and MTX IR vs. INT/inappro-
priate (monotherapy study). Further details of the sub-
groups, as well as exploratory analyses performed post
hoc for all 3 studies, are described in Additional file 1.
Endpoints
Primary endpoints
Efficacy was assessed in patient subpopulations for the
coprimary/primary endpoints of each study: American Col-
lege of Rheumatology 20% (ACR20) response at week 24,
change from baseline in the Health Assessment
Questionnaire-Disability Index (HAQ-DI) at week 16,
and change from baseline in the modified total
Sharp/van der Heijde score (mTSS) at week 52 for
the MTX-IR combination study; ACR20 at week 24
and change from baseline in the HAQ-DI at week 12
for the TNF-IR/INT combination study; and change
from baseline in the Disease Activity Score in 28
joints using ESR (DAS28-ESR) at week 24 for the
monotherapy study.
Secondary endpoints
Secondary efficacy endpoints for subanalyses at week 24
included ACR20 (monotherapy study), ACR 50%
response (ACR50), and ACR 70% response (ACR70);
DAS28-ESR remission (< 2.6; monotherapy study only);
mean change from baseline in DAS28 using CRP
(DAS28-CRP); proportion of patients achieving
DAS28-CRP < 2.6; mean change from baseline in
HAQ-DI ≥ 0.22 (established threshold for minimal
clinically important difference [20]) and ≥ 0.3 [17, 18,
20–22] units of improvement in HAQ-DI; mean
change in Clinical Disease Activity Index (CDAI) and Sim-
plified Disease Activity Index (SDAI) from baseline to week
24; CDAI remission (≤ 2.8); and SDAI remission (≤ 3.3).
Improvements from baseline ≥ 58% and ≥ 85% in
CDAI and SDAI were defined post hoc as exploratory
subanalyses, as they have been shown at week 12 to sen-
sitively predict low disease activity (≥ 58%) and remission
(≥ 85%) at 6 months [23].
Safety was reported as the occurrence of treatment-
emergent adverse events (TEAEs), serious TEAEs
(SAEs), serious infections, and specific abnormalities in
laboratory parameters. Adverse events (AEs) were de-
scribed at the Medical Dictionary for Regulatory Activ-
ities (version 16.0) preferred term level. Proportions of
patients with grade 3 (absolute neutrophil count
[ANC] ≥ 0.5–1 × 109/L) and grade 4 (ANC < 0.5 × 109/L)
neutropenia were assessed.
Statistical analyses
Subanalyses of efficacy and safety by patient subpopula-
tion were conducted with the intention-to-treat and safety
populations, respectively. In the sarilumab monotherapy
study, the comparison of sarilumab 200mg q2w with ada-
limumab included a minority of patients (n = 16), who in-
creased adalimumab dose to 40mg every week, in
addition to those receiving 40mg q2w (n = 169).
For categorical efficacy variables, patients were consid-
ered non-responders from the time they discontinued
study medication or started rescue medication; missing
values were set to non-response. Mantel-Haenszel esti-
mates of the odds ratio (OR) with corresponding 95%
confidence intervals (CIs), stratified by region and prior
bDMARDs (MTX-IR combination study only) or prior
anti-TNFs (TNF-IR/INT combination study only), were
derived by testing each treatment group separately by
subpopulation.
Treatment-by-subgroup interaction was tested using lo-
gistic regression with baseline and terms of treatment, study
stratification variables, subpopulation, and treatment-by-
subpopulation. The interaction p value from treatment-by-
subgroup or from treatment-by-visit-by-subpopulation at
the visit of interest was used to assess the treatment effect
differences across subpopulations. p values for all analyses
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should be considered nominal. Analysis of safety by age
was also conducted post hoc.
For continuous efficacy variables, assessments were set
to missing from the time a patient discontinued study
medication early or received rescue medication; missing
values were not imputed. The least-squares mean (LSM)
difference and corresponding 95% CIs were derived from
a mixed-effects model for repeated measures, assuming an
unstructured covariance structure with covariate baseline
and terms of treatment, study stratification variables, sub-




Baseline demographics and patient characteristics for
the three study populations have been reported previ-
ously [17–19] and were generally well balanced between
the treatment groups in each individual study and are
summarized in Table S1 (see Additional file 1).
Efficacy
The superiority of sarilumab 150/200mg q2w +MTX/
csDMARDs vs. placebo +MTX/csDMARDs and of
sarilumab 200 mg monotherapy vs. adalimumab mono-
therapy in the overall study populations has been previ-
ously reported for the prespecified primary and
secondary endpoints [17–19]. The efficacy of sarilumab
(+ csDMARDs or as monotherapy) in patient subgroups
is described in Figs. 1, 2, 3, and 4 and Figures S1–S6
(see Additional file 1). Treatment interaction p values
are shown in Table 1.
Age and sex
No treatment-by-subgroup interaction p values < 0.05
were found for subpopulations defined by age or sex for
ACR responses, CDAI-based endpoints, and DAS28-based
endpoints (Table 1). In the MTX-IR combination study,
there were also no interaction p values < 0.05 for age or
sex and change from baseline in mTSS (Table 1). In the
TNF-IR/INT combination study, the 95% CI was wide
and crossed 0 for change from baseline in HAQ-DI at
week 12 in male patients (Figure S5 (Additional file 1);
Table 1). In each of the three studies, ORs or LSM treat-
ment differences favoured both doses of sarilumab com-
bination therapy over placebo + csDMARDs or sarilumab
monotherapy over adalimumab across the majority of
endpoints independent of age or sex (Figs. 1, 2, and 3 and
Figures S1, S3, S6 (Additional file 1)).
Race and region
No treatment-by-subgroup interaction p values < 0.05
were reported for any endpoints for race or region for
the MTX-IR combination study and the monotherapy
study (Table 1). ORs and LSM treatment differences
consistently favoured sarilumab treatment over placebo or
adalimumab across the majority of endpoints independent
of race or region (Fig. 2, Figures S1, S3, S4, S6 (Add-
itional file 1)). In the TNF-IR/INT combination study, ORs
and LSM treatment differences consistently favoured sarilu-
mab + csDMARDs over placebo + csDMARDs on all effi-
cacy endpoints assessed for subgroups defined by race or
region except for CDAI remission for non-white patients
(i.e. race ‘others’; n = 158). However, the 95% CI for this
point estimate was wide and crossed 0 (Figure S4B (Add-
itional file 1)). An interaction test with a nominal p < 0.05
was found between race and ACR20 and ACR50 response
(p = 0.03 and p = 0.02) and CDAI remission (p < 0.01), but
not for ACR70 and CDAI improvement ≥ 58% (Table 1).
Weight and BMI
LSM treatment differences generally favoured sarilumab
(± csDMARDs) over placebo + csDMARDs or adalimu-
mab, irrespective of weight category for change from
baseline in DAS28-CRP (Fig. 2), CDAI (Figure S3 (Add-
itional file 1)), and mTSS (assessed only in the MTX-IR
combination study, Figure S6 (Additional file 1)). ORs
also favoured sarilumab over placebo + csDMARDs for
(See figure on previous page.)
Fig. 1 Odds ratio (95% CI) for ACR20 response by subpopulation at week 24. a Sarilumab 150/200mg q2w +MTX vs. placebo +MTX in MTX-IR
patients. b Sarilumab 150/200 mg q2w + csDMARDs vs. placebo + csDMARDs in TNF-IR/INT patients. c Sarilumab 200 mg q2w vs.
adalimumab 40mg q2w in MTX-IR/INT patients. Mantel-Haenszel estimate with terms of treatment: a treatment, prior biologic use, region,
subpopulation, and treatment-by-subpopulation; b treatment, prior anti-TNF use, region, subpopulation, and treatment-by-subpopulation; and c
treatment, region, subpopulation, and treatment-by-subpopulation. ACPA, anti-cyclic citrullinated peptide antibody; ACR20, American College of
Rheumatology 20% response; bDMARD, biological and targeted disease-modifying antirheumatic drug; BMI, body mass index; CI, confidence interval;
CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HDA, high
disease activity; INT, intolerant; IR, inadequate response; MTX, methotrexate; n, number of evaluable patients regardless of the treatment group; q2w,
every 2 weeks; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; TNF, tumour necrosis factor; ULN, upper limit of
normal. *Austria, Australia, Belgium, Canada, Finland, Germany, Greece, Hungary, New Zealand, Norway, Portugal, Spain, and USA; †Argentina, Brazil,
Chile, Colombia, and Mexico; ‡Belarus, Estonia, India, Malaysia, Philippines, Poland, Romania, Russia, South Africa, South Korea, Taiwan, Thailand, and
Ukraine; §Australia, Canada, Czech Republic, Germany, Greece, Hungary, Israel, Italy, New Zealand, Portugal, Spain, and USA; ‖Argentina, Brazil, Chile,
Colombia, Ecuador, Guatemala, Mexico, and Peru; ¶South Korea, Lithuania, Poland, Russia, Taiwan, Turkey, and Ukraine; **Czech Republic, Germany,
Hungary, Israel, Spain, and USA; ††Chile and Peru; ‡‡South Korea, Poland, South Africa, Romania, Russia, and Ukraine
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CDAI remission irrespective of weight category (Figure
S4 (Additional file 1)), and treatment-by-subgroup inter-
action p values were ≥ 0.05 for all endpoints (Table 1).
Altogether, 95% CIs for weight categories were wide and
overlapping for all endpoints.
For BMI, interaction-by-subgroup p values were ≥ 0.05
for the two combination studies (with the exception of
DAS28-CRP in the MTX-IR combination study). ORs
and LSM treatment differences favoured sarilumab
150/200mg over placebo +MTX regardless of BMI sub-
group in the MTX-IR and TNF-IR/INT combination
studies across all efficacy endpoints. In the monotherapy
study, however, interactions with nominal p < 0.05 (indi-
cating a difference in sarilumab efficacy) were found for
BMI across most efficacy endpoints compared to adalimu-
mab (Table 1). BMI < 25 kg/m2 and ≥ 25 to < 30 kg/m2
was associated with more robust sarilumab responses than
BMI ≥ 30 kg/m2 for several efficacy endpoints, including
those based on ACR, CDAI, and HAQ-DI.
Baseline autoantibody status
Across the three studies, treatment-by-subgroup
interaction values p < 0.05 (indicating an effect of
baseline ACPA status) were consistently observed for
ACR20 (Table 1). Compared with patients who were
ACPA negative at baseline, LSM treatment differ-
ences and ORs consistently demonstrated a
numerically greater treatment effect for most end-
points with sarilumab (± csDMARDs) for patients
who were ACPA positive at baseline, particularly
with the 200 mg sarilumab dose (sarilumab 200 mg;
n = 337 and n = 137 in the MTX-IR and TNF-IR/INT
combination studies, respectively).
Treatment-by-subgroup interaction p values < 0.05
were not consistently observed for any endpoint
across the three studies for RF status at baseline.
Among RF-negative patients in the MTX-IR combin-
ation study (200 mg group, n = 69), although ORs and
LSMs appeared to favour 200 mg sarilumab +MTX
for some endpoints, treatment-by-subgroup p values were
all ≥ 0.05 (suggesting sarilumab efficacy may not be im-
pacted overall by RF status). Similarly, among RF-negative
patients in the TNF-IR/INT combination study, ORs
and LSMs appeared to favour 200 mg sarilumab +
csDMARDs for some endpoints; however, treatment
interactions for RF status had nominal p < 0.05 only
for ACR20/50, CDAI ≥ 58%, and change from baseline
in HAQ-DI. In the monotherapy study, the only sig-
nificant treatment interaction p value for RF status
was for ACR20 (Table 1).
Safety
As reported previously, across the three sarilumab RCTs
and in a large, long-term safety analysis, the most fre-
quent AEs were neutropenia, increased alanine amino-
transferase (ALT), injection site erythema, upper
respiratory infections, urinary tract infections, nasophar-
yngitis, and bronchitis [17–19, 24].
Due to the particular concern for the safety and tol-
erability of treatments in patients aged ≥ 65 years, we
assessed AEs in this population. TEAEs and SAEs oc-
curred more frequently in the small group of patients
aged ≥ 65 years (n = 289) compared with patients aged
< 65 years (n = 1819) for the placebo, sarilumab, and
adalimumab treatment groups (Table 2). Infections
were the most common TEAEs in both age groups
treated with sarilumab, but serious infections were
uncommon (Table 2).
In general, no appreciable differences were observed
between subpopulations ≥ 65 and < 65 years for labora-
tory parameters, such as ANC, platelets, and ALT. In
the MTX-IR combination study and monotherapy study,
the proportion of patients with ANC < 1.5 × 109/L was
comparable in both age groups across all treatment
groups. In the TNF-IR/INT combination study,
compared with patients aged < 65 years, a higher pro-
portion of patients aged ≥ 65 years had ANC < 1.5 ×
109/L across placebo and sarilumab treatment groups:
(See figure on previous page.)
Fig. 2 LSM (95% CI) treatment difference for change from baseline in DAS28-CRP at week 24. a Sarilumab 150/200mg q2w +MTX vs. placebo +
MTX in MTX-IR patients. b Sarilumab 150/200mg q2w + csDMARDs vs. placebo + csDMARDs in TNF-IR/INT patients. c Sarilumab 200 q2w vs.
adalimumab 40 mg q2w in MTX-IR/INT patients. Mixed-effect model for repeated measures with PROC MIXED assuming an unstructured
covariance structure: a baseline, treatment, prior biologic use, region, visit, and treatment-by-visit interaction; b baseline, treatment, prior anti-TNF
use, region, visit, and treatment-by-visit interaction; and c baseline, treatment, region, visit, and treatment-by-visit interaction. ACPA, anti-cyclic
citrullinated peptide antibody; bDMARD, biological and targeted disease-modifying antirheumatic drug; BMI, body mass index; CI, confidence
interval; CRP, C-reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28-CRP, Disease Activity Score
in 28 joints using CRP; ESR, erythrocyte sedimentation rate; HDA, high disease activity; INT, intolerant; IR, inadequate response; LSM, least squares mean;
MTX, methotrexate; n, number of evaluable patients regardless of the treatment group; q2w, every 2 weeks; RA, rheumatoid arthritis; RF, rheumatoid
factor; SDAI, Simplified Disease Activity Index; TNF, tumour necrosis factor; ULN, upper limit of normal. *Austria, Australia, Belgium, Canada, Finland,
Germany, Greece, Hungary, New Zealand, Norway, Portugal, Spain, and USA; †Argentina, Brazil, Chile, Colombia, and Mexico; ‡Belarus, Estonia, India,
Malaysia, Philippines, Poland, Romania, Russia, South Africa, South Korea, Taiwan, Thailand, and Ukraine; §Australia, Canada, Czech Republic, Germany,
Greece, Hungary, Israel, Italy, New Zealand, Portugal, Spain, and USA; ‖Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Mexico, and Peru; ¶South
Korea, Lithuania, Poland, Russia, Taiwan, Turkey, and Ukraine; **Czech Republic, Germany, Hungary, Israel, Spain, and USA; ††Chile and Peru; ‡‡South
Korea, Poland, South Africa, Romania, Russia, and Ukraine
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3.4% (n = 1/29) vs. 0.7% (n = 1/152) with placebo +
csDMARDs, 22.6% (n = 7/31) vs. 16.0% (n = 24/150)
with sarilumab 150 mg q2w + csDMARDs, and 33.3%
(n = 10/30) vs. 20.8% (n = 32/154) with sarilumab 200mg
q2w + csDMARDs (Table 2). Proportions of patients
with platelets < 50 × 109/L were low in all age/treatment
groups (≤ 0.6%).
Discussion
These subanalyses of three separate, phase III RCTs,
which included patients with active RA, demonstrated
that sarilumab consistently improved signs and symp-
toms of RA, physical functioning, and radiographic pro-
gression across a wide range of patient subpopulations,
representing a broad range of patients.
Long-term safety data for sarilumab treatment have
previously been reported [24]. Our analysis here was
consistent with previous analyses of safety data in the
pooled population, which showed no clear differences in
the safety profile of sarilumab between patient sub-
groups, although a slightly higher proportion of patients
aged ≥ 65–< 75 years reported serious infections in the
sarilumab 150 mg q2w + csDMARD group vs. those aged
≥ 75 years: 4/79 (5.1%) vs. 8/574 (1.4%) in the placebo-
controlled safety population [25].
In the present analysis, whilst the patient population
aged ≥ 65 years was small, limiting interpretation of
these data, higher rates of SAEs, and serious infec-
tions were observed in these patients compared to
those aged < 65 years; however, no appreciable
differences were observed between patients aged < 65
vs. ≥ 65 years for ANC, ALT, and platelet count.
Safety and tolerability are a specific potential concern
in this subpopulation, and AEs are among the main
causes of discontinuation of RA therapy among older
patients [26]. An increase in comorbidities, such as
diabetes mellitus and renal disease, in older patients
vs. younger patients or more frequent use of oral gluco-
corticoids has been suggested to increase the risk of
infections [27–29]. Previous studies have also re-
ported an increased risk of serious infections in RA
patients > 60 years of age compared with younger pa-
tients [30–32], but no significant difference was found
in the rate of infection between the ages of 65–74 and
≥ 75 years [30].
In interpreting our findings, it is critical to under-
stand the appropriate statistical methodology for
assessing whether treatment effects vary across levels
of a baseline variable/characteristic. A common error
is to conduct separate tests of treatment effects
within each of the levels of the baseline variable or to
evaluate the observed treatment effect sizes within
each subgroup [33]; the correct approach is to con-
duct a statistical test for interaction [33]. An inter-
action test with nominal p < 0.05 suggests that the
baseline variable has an impact on the treatment ef-
fect and, in itself, does not indicate how the effect of
treatment differs across the baseline characteristic. In
our analysis, the interaction test also does not differ-
entiate between the two sarilumab doses evaluated in
the placebo-controlled studies; furthermore, it was
not the aim of this analysis to compare the two ap-
proved doses. Taking a conservative approach, in our
analysis, we have noted the subgroups for which the
interaction test had a nominal p < 0.05; however, it
has been suggested that a preferable way of assessing
the p value is that as it gets smaller, the subgroup hy-
pothesis becomes increasingly credible and should
only be taken seriously when p values reach 0.001 or
less [34]. Additionally, we should appreciate that the
probability of a false-positive finding increases when
multiple subgroup analyses are performed and that
criteria to assess the credibility of subgroup analyses
should include whether the interaction is consistent
across studies and consistent across closely related
outcomes within the study [34]. In our analysis, inter-
action tests with nominal p < 0.05 that were consistent
across the studies were only seen for baseline ACPA
(See figure on previous page.)
Fig. 3 Odds ratio (95% CI) for improvement in CDAI ≥58% at week 24 by subpopulation. a Sarilumab 150/200mg q2w +MTX vs. placebo + MTX
in MTX-IR patients. b Sarilumab 150/200mg q2w + csDMARDs vs. placebo + csDMARDs in TNF-IR/INT patients. c Sarilumab 200mg q2w vs.
adalimumab 40 mg q2w in MTX-IR/INT patients. Logistic regression model with terms of a treatment, prior biologic use, region, subpopulation,
and treatment-by-subpopulation; b treatment, prior anti-TNF use, region, subpopulation, and treatment-by-subpopulation; and c treatment,
region, subpopulation, and treatment-by-subpopulation. ACPA, anti-cyclic citrullinated peptide antibody; bDMARD, biological and targeted
disease-modifying antirheumatic drug; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; csDMARD, conventional synthetic
disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; ESR, erythrocyte sedimentation rate; HDA, high disease activity; INT,
intolerant; IR, inadequate response; MTX, methotrexate; n, number of evaluable patients regardless of the treatment group; q2w, every 2 weeks;
RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; TNF, tumour necrosis factor; ULN, upper limit of normal.
*Austria, Australia, Belgium, Canada, Finland, Germany, Greece, Hungary, New Zealand, Norway, Portugal, Spain, and USA; †Argentina, Brazil, Chile,
Colombia, and Mexico; ‡Belarus, Estonia, India, Malaysia, Philippines, Poland, Romania, Russia, South Africa, South Korea, Taiwan, Thailand, and
Ukraine; §Australia, Canada, Czech Republic, Germany, Greece, Hungary, Israel, Italy, New Zealand, Portugal, Spain, and USA; ‖Argentina, Brazil,
Chile, Colombia, Ecuador, Guatemala, Mexico, and Peru; ¶South Korea, Lithuania, Poland, Russia, Taiwan, Turkey, and Ukraine; **Czech Republic,
Germany, Hungary, Israel, Spain, and USA; ††Chile and Peru; ‡‡South Korea, Poland, South Africa, Romania, Russia, and Ukraine
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Fig. 4 (See legend on next page.)
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status for ACR20 (but not ACR50 nor ACR70) and
for no other baseline variable evaluated.
ACPA-positive and RF-positive RA are associated
with worse prognoses and erosive disease [7–9]. Ac-
knowledging the reliability criteria above, it was inter-
esting to note interaction p values were < 0.05 for
ACR20 (but not for ACR50 and ACR70), with forest
plots indicating sarilumab may be more effective in RA
patients who are ACPA positive. An effect of autoanti-
body status on efficacy has been observed for other bio-
logic treatments; ACPA-positive status at baseline was
associated with a superior response to both adalimu-
mab and abatacept in the AMPLE study [11]. Further-
more, responses to abatacept were greater in those
patients with high titres of ACPA at baseline, although
this association was not observed for adalimumab [11].
Responses to rituximab as well as csDMARDs ± gluco-
corticoids have also been reported to differ by ACPA
status [14, 35]. In contrast, analyses of IL-6 receptor
(IL-6R) inhibition with tocilizumab have not identified
a relationship between baseline ACPA or RF status and
achievement of response and remission [36, 37]. In
our analysis, treatment interaction p values for RF
status were not < 0.05 consistently across studies; indeed,
p values ≥ 0.05 were observed for all endpoints in the lar-
gest of the three studies. As seronegative patients may
have less aggressive disease, it may be more difficult
to determine a treatment difference in these patients.
Additionally, based on the inclusion/exclusion criteria
for the three pivotal phase III sarilumab studies, there
were fewer seronegative patients enrolled, and the
smaller sample size means that these data may be less
reliable.
In the analysis presented here, we found no effect
of baseline weight on sarilumab efficacy. There was
also no indication that baseline BMI impacts the effi-
cacy of sarilumab + csDMARDs. In the monotherapy
study, potential interactions with baseline BMI were
identified; however, this observation and the lack of
interaction with baseline weight in the monotherapy
study are inconsistent.
Although no consistent treatment-by-subgroup inter-
actions were seen for baseline CRP in the combination
studies, potential interactions were identified for baseline
CRP for some endpoints assessed in the monotherapy
trial, with a greater magnitude of effect in patients with
CRP > 15 mg/L at baseline. These interactions were not
observed in the related subgroup categorized by baseline
erythrocyte sedimentation rate (ESR), and the efficacy
results in the subgroups categorized by baseline CRP
were consistent with the main results. Change in CRP
levels in the initial weeks following treatment initiation
has been reported to predict response to TNF inhibitors
[38, 39]. Our findings are also consistent with some
studies of IL-6R inhibition with tocilizumab, which have
reported a greater EULAR response in patients with high
baseline CRP [37].
The different inclusion criteria of the three studies have
already provided some insight that sarilumab is effective
in patients with RA irrespective of prior therapies
[17–19]. Our analysis provides more information on
the effects of prior treatments with csDMARDs (num-
ber of prior agents and INT or IR to MTX) and
bDMARDs (including whether patients had received
one or more prior treatment) and found no differ-
ences in the efficacy of sarilumab across endpoints.
We also evaluated the effect of stable glucocorticoid
use and observed no treatment-by-subgroup inter-
action for sarilumab + csDMARDs. Interactions for
baseline glucocorticoid use were not seen consistently
across endpoints in the monotherapy study.
A limitation of the present analysis is that the study
populations recruited in the three individual trials dif-
fered temporally, spatially (i.e. by geographical location),
and by prior treatment history and response to previous
treatment; thus, results across the studies cannot be
compared directly. In addition, there were some differ-
ences between the prespecified subpopulations. The
(See figure on previous page.)
Fig. 4 Odds ratio (95% CI) for HAQ-DI improvement ≥ 0.22 units at week 24 by subpopulation. a Sarilumab 150/200mg q2w +MTX vs. placebo +
MTX in MTX-IR patients. b Sarilumab 150/200mg q2w + csDMARDs vs. placebo + csDMARDs in TNF-IR/INT patients. c Sarilumab 200mg q2w vs.
adalimumab 40 mg q2w in MTX-IR/INT patients. Logistic regression model with terms of a treatment, prior biologic use, region, subpopulation,
and treatment-by-subpopulation; b treatment, prior anti-TNF use, region, subpopulation, and treatment-by-subpopulation; and c treatment,
region, subpopulation, and treatment-by-subpopulation. ACPA, anti-cyclic citrullinated peptide antibody; bDMARD, biological and targeted
disease-modifying antirheumatic drug; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; csDMARD, conventional synthetic
disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; HDA, high
disease activity; INT, intolerant; IR, inadequate response; MTX, methotrexate; n, number of evaluable patients regardless of the treatment group;
q2w, every 2 weeks; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; TNF, tumour necrosis factor; ULN,
upper limit of normal. *Austria, Australia, Belgium, Canada, Finland, Germany, Greece, Hungary, New Zealand, Norway, Portugal, Spain, and USA;
†Argentina, Brazil, Chile, Colombia, and Mexico; ‡Belarus, Estonia, India, Malaysia, Philippines, Poland, Romania, Russia, South Africa, South Korea,
Taiwan, Thailand, and Ukraine; §Australia, Canada, Czech Republic, Germany, Greece, Hungary, Israel, Italy, New Zealand, Portugal, Spain, and USA;
‖Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Mexico, and Peru; ¶South Korea, Lithuania, Poland, Russia, Taiwan, Turkey, and Ukraine;
**Czech Republic, Germany, Hungary, Israel, Spain, and USA; ††Chile and Peru; ‡‡South Korea, Poland, South Africa, Romania, Russia, and Ukraine
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Table 1 Treatment-by-subpopulation interactions across all three trials: endpoints at week 24 (unless otherwise stated)
















MTX-IR combination study 0.4673 0.6419 0.8516 0.7974 – 0.7638 0.9784 0.4889 0.9232 0.5847 0.5570
TNF-IR/INT combination study 0.4095 0.7902 0.2886 0.4695 – 0.6915 0.1337 0.5813 0.8173 0.4101 –
Monotherapy study 0.9861 0.6249 0.8440 0.9712 0.8819 0.5079 0.5501 0.6872 0.3983 0.7994 –
Sex
MTX-IR combination study 0.7934 0.7803 0.0643 NC – 0.3802 0.4315 0.3500 0.6165 0.4633 0.5890
TNF-IR/INT combination study 0.6818 0.2610 0.2086 0.4134 – 0.5132 0.0614 0.7993 0.2999 0.0417 –
Monotherapy study 0.7733 0.2587 0.0944 0.6394 0.1953 0.6325 0.6609 0.6818 0.8029 0.1981 –
Race
MTX-IR combination study 0.4769 0.4827 0.3125 0.7798 – 0.5666 0.5479 0.3820 0.7486 0.2893 0.6911
TNF-IR/INT combination study 0.0337 0.0154 0.0529 0.3539 – 0.3740 0.0035 0.4085 0.1012 0.6925 –
Monotherapy study 0.2497 0.5923 0.9450 0.6376 0.6242 0.8933 0.9985 0.3730 0.1100 0.6447 –
Region
MTX-IR combination study 0.5715 0.7835 0.7406 0.2041 – 0.1234 0.3924 0.4628 0.8182 0.3900 0.4490
TNF-IR/INT combination study 0.7319 0.5572 0.3057 0.9603 – 0.9703 0.4381 0.5830 0.5106 0.9414 –
Monotherapy study 0.1965 0.2636 0.5468 0.9506 0.6213 0.8280 0.9865 0.7148 0.1223 0.1202 –
Weight
MTX-IR combination study 0.5261 0.6026 0.2398 NC – NC 0.7471 0.9225 0.4171 NC 0.3874
TNF-IR/INT combination study 0.2172 0.9392 0.0593 0.2256 – 0.7918 0.1423 0.5359 0.2759 0.2538 –
Monotherapy study 0.2376 0.4871 0.1161 0.3297 0.2533 0.1991 0.9981 0.5408 0.0939 0.2366 –
BMI
MTX-IR combination study 0.0539 0.7636 0.4607 0.0166 – 0.1116 0.8669 0.5427 0.3684 0.6091 0.1167
TNF-IR/INT combination study 0.3219 0.5705 0.4019 0.1699 – 0.5089 0.4425 0.0593 0.8816 0.4860 –
Monotherapy study 0.0048 0.0186 0.0117 0.0231 0.0466 0.0239 0.0608 0.0492 < 0.0001 0.0023 –
Smoking history
MTX-IR combination study 0.8811 0.7700 0.5258 NC – 0.9072 0.4806 0.5732 0.4258 0.1465 0.2046
TNF-IR/INT combination study 0.4588 0.9214 0.3633 0.2900 – 0.2582 0.3958 0.1818 0.6147 0.7203 –
Monotherapy study 0.2545 0.4051 0.3061 0.6974 0.3829 0.4994 0.6053 0.7733 0.1321 0.4093 –
Duration RA (</≥ 2 years)
MTX-IR combination study 0.5211 0.4003 0.1108 0.3018 – 0.0611 0.3217 0.1550 0.3796 0.3297 NC
TNF-IR/INT combination study 0.7880 0.8392 0.0778 0.7489 – 0.8370 0.2069 0.9211 0.9795 0.8628 –
Monotherapy study 0.6300 0.8484 0.6729 0.2816 0.4205 0.5917 0.5604 0.9527 0.7008 0.0512 –
Duration RA (</≥median)
MTX-IR combination study 0.8364 0.5116 0.1697 0.7286 – 0.7994 0.1961 0.1578 0.9931 0.5678 0.3215
TNF-IR/INT combination study 0.0516 0.1992 0.1678 0.3154 – 0.2261 0.2482 0.0951 0.2263 0.1228 –
Monotherapy study 0.2995 0.8856 0.8174 0.2916 0.8227 0.6843 0.4439 0.8276 0.2054 0.3787 –
RF
MTX-IR combination study 0.1083 0.3854 0.0564 0.0551 – 0.6429 0.1869 0.0766 0.0721 0.0427 0.8194
TNF-IR/INT combination study 0.0012 0.0480 0.3007 0.0887 – 0.0528 0.2175 0.0070 0.0996 0.0202 –
Monotherapy study 0.0416 0.6937 0.7953 0.2139 0.6410 0.1476 0.4715 0.4768 0.7497 0.7273 –
ACPA
MTX-IR combination study 0.0010 0.0897 0.1654 0.0012 – 0.0024 0.4017 0.0566 0.0490 0.0028 0.9994
TNF-IR/INT combination study 0.0453 0.2511 0.8391 0.0866 – 0.0379 0.9770 0.0071 0.5114 0.0929 –
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duration of the studies and small numbers of patients in
some subpopulations also limit the interpretation of the
data. The inherent limitations of conducting multiple
subgroup analyses should also be noted, with the prob-
ability of a false-positive finding increasing with the
number of analyses performed [33]; indeed, several of
the treatment-by-subgroup interactions identified in
the current analysis were not replicated on related end-
points. However, within similar backgrounds and sari-
lumab regimens, some trends were noted. It is likely
that treatment responses in patients with RA are influ-
enced by a combination of baseline characteristics ra-
ther than isolated characteristics, and additional
analyses with larger subpopulations are warranted to
investigate this further.
Conclusions
In patients with RA and MTX-IR/INT or TNF-IR/INT,
sarilumab (± csDMARDs) demonstrated superiority to
placebo (± csDMARDs) or adalimumab for clinical effi-
cacy measures across many patient subpopulations.
Apart from ACPA status, there were no consistent sig-
nals indicating differential effects of sarilumab in any of
the subpopulations assessed. A larger treatment effect
was observed for sarilumab 200 mg q2w in the MTX-IR
and TNF-IR/INT combination studies among patients
who were seropositive (RF or ACPA) at baseline and for
those with lower BMI (< 30 kg/m2) at baseline. These
data suggest that treatment with sarilumab is associated
with beneficial effects across a broad spectrum of pa-
tients who have RA.
Table 1 Treatment-by-subpopulation interactions across all three trials: endpoints at week 24 (unless otherwise stated) (Continued)















Monotherapy study 0.0028 0.9442 0.1778 0.1462 0.4771 0.4249 0.5984 0.5878 0.0316 0.0337 –
Baseline CRP
MTX-IR combination study 0.9068 0.5979 0.6065 0.0537 – 0.2589 0.4199 0.3974 0.3455 0.2497 0.0221
TNF-IR/INT combination study 0.0948 0.3845 0.6999 0.8008 – 0.8900 0.4386 0.1774 0.0159 0.6836 –
Monotherapy study 0.0314 0.0759 0.0101 0.0074 0.0055 0.0152 0.5015 0.1328 0.0570 0.0006 –
Baseline ESR
Monotherapy study 0.5073 0.8452 0.9318 0.7010 0.1295 0.5070 0.0123 0.9278 0.2552 0.6488 –
Baseline SDAI
MTX-IR combination study 0.5963 0.5269 0.4816 0.1452 – 0.0399 0.9009 0.7552 0.6002 0.5804 0.7226
TNF-IR/INT combination study 0.5986 0.9399 0.5674 NC – NC 0.4333 0.1970 0.2160 NC –
Prior bDMARD
MTX-IR combination study 0.8583 0.5175 0.1973 0.9345 – 0.8793 0.2421 0.2202 0.8858 0.6812 0.2246
Prior anti-TNFs
TNF-IR/INT combination study 0.1215 0.2340 0.0925 0.2052 – 0.2210 0.1916 0.2797 0.2853 0.3850 –
Prior csDMARDs
MTX-IR combination study 0.4208 0.4886 0.6909 0.3946 – 0.1183 0.8905 0.2846 0.9064 0.9111 0.3586
TNF-IR/INT combination study 0.4941 0.6441 0.3744 0.3431 – 0.1108 0.6155 0.8227 0.2881 0.7416 –
Monotherapy study 0.7935 0.2370 0.6967 0.8694 0.3740 0.5514 0.5602 0.5459 0.3767 0.9655 –
Background csDMARDs
TNF-IR/INT combination study 0.3194 0.6946 0.3646 0.1658 – 0.5573 0.2718 0.3391 0.5595 0.8590 –
MTX history
Monotherapy study 0.5540 0.3982 0.3313 0.2163 0.2163 0.2583 0.6631 0.1498 0.3692 0.6913 –
Glucocorticoid use
MTX-IR combination study 0.5072 0.6390 0.8555 0.3366 – 0.3784 0.7197 0.8891 0.1751 0.7058 0.9422
TNF-IR/INT combination study 0.2751 0.9400 0.8334 0.6142 – 0.6061 0.0656 0.5640 0.0994 0.8873 –
Monotherapy study 0.0907 0.1650 0.9422 0.0663 0.0414 0.0195 0.4352 0.0025 0.0962 0.7536 –
ACPA anti-cyclic citrullinated peptide antibody, ACR20/50/70 American College of Rheumatology 20%/50%/70% response, bDMARD biological and targeted
disease-modifying antirheumatic drug, BMI body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-
modifying antirheumatic drug, DAS28-CRP Disease Activity Score in 28 joints using CRP, DAS28-ESR Disease Activity Score in 28 joints using erythrocyte
sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, INT intolerant, IR inadequate response, NC not calculated, mTSS Modified Total
Sharp Score, MTX methotrexate, RA rheumatoid arthritis, RF rheumatoid factor, SDAI Simplified Disease Activity Index, TNF tumour necrosis factor
*Assessed at week 16/12/24 in the MTX-IR combination study, TNF-IR/INT combination study, and monotherapy studies, respectively
**Assessed at week 52
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